| 阿柏西普在眼科疾病治疗中的应用 |
| |
| 引用本文： | 张国明,田娅.阿柏西普在眼科疾病治疗中的应用[J].眼科新进展,2020,0(1):001-5. |
| |
| 作者姓名： | 张国明 田娅 |
| |
| 作者单位： | 518040 广东省深圳市，暨南大学第二临床学院深圳市眼科医院、深圳大学眼视光学院（张国明，田娅）；550004 贵州省贵阳市，贵州医科大学（田娅） |
| |
| 基金项目： | 深圳市学科布局项目(编号:JCYJ20170817112542555) |
| |
| 摘 要： | 阿柏西普是一种与血管内皮生长因子-A、B及胎盘生长因子特异性结合的人源化重组融合蛋白，其通过降低血管内皮通透性进而抑制新生血管生成，在病理性血管形成过程中扮演重要角色。近年来，该药在医学领域的应用范围不断扩大，在结直肠癌、卵巢癌、糖尿病性黄斑水肿、老年性黄斑变性、视网膜静脉阻塞及早产儿视网膜病变等治疗中均被广泛应用，并取得较好效果。本文旨在综述阿柏西普的药理学特点及其在眼科疾病中的应用现状、治疗优势，为后续药物研究和临床应用提供更多的治疗策略。
|
| 关 键 词： | 阿柏西普 血管内皮生长因子 眼科 |
Advances in application of Aflibercept for treatment of ocular diseases |
| |
| ZHANG Guoming,TIAN Ya.Advances in application of Aflibercept for treatment of ocular diseases[J].Recent Advances in Ophthalmology,2020,0(1):001-5. |
| |
| Authors: | ZHANG Guoming TIAN Ya |
| |
| Institution: | 1.Shenzhen Eye Hospital,the Second Clinical College of Jinan University Shenzhen Eye Hospital,the School of Optometry & Ophthalmology of Shenzhen University,Shenzhen 518040,Guangdong Province,China2.Guizhou Medical University,Guiyang 550004,Guizhou Province,China |
| |
| Abstract: | Aflibercept is a humanized recombinant fusion protein that specifically binds to vascular endothelial growth factor-A,B and placental growth factor.It plays an important role in pathological angiogenesis by reducing vascular endothelial permeability and thereby inhibiting neovascularization.In recent years,Aflibercept has been widely used in the treatment of colorectal cancer,ovarian cancer,diabetic macular edema,age-related macular degeneration,retinal vein occlusion and retinopathy of prematurity,and achieved good results.The article has reviewed the pharmacological characteristics of Aflibercept and its current application status and therapeutic advantages in ocular diseases,so as to provide more treatment strategies for subsequent drug research and clinical drug selection. |
| |
| Keywords: | Aflibercept vascular endothelial growth factor ophthalmology |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《眼科新进展》浏览原始摘要信息 |
| 点击此处可从《眼科新进展》下载免费的PDF全文 |
|
